key: cord-0835985-p79ck2z8
authors: Rhee, Chanu; Baker, Meghan A; Kanjilal, Sanjat; Tucker, Robert; Vaidya, Vineeta; Badwaik, Amy; Blaeser, Elizabeth Mermel; Coughlin, Cassie; Elloyan, Jennifer; Hsieh, Candace; Holtzman, Meghan; Solem, Ofelia; Klompas, Michael
title: Prospective Clinical Assessments of Hospitalized Patients with Positive SARS-CoV-2 PCR Tests for Necessity of Isolation
date: 2021-04-16
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab194
sha: e1c65736bfd4eb2a9af9d48432850a5bdfde7b49
doc_id: 835985
cord_uid: p79ck2z8

We prospectively assessed 536 hospitalized patients with positive SARS-CoV-2 PCR tests for infectiousness based on symptoms, cycle thresholds, and SARS-CoV-2 history, with repeat testing and serologies in select cases. 148 (28%) patients were deemed non-infectious, most with evidence of prior infection, and managed on standard precautions without evidence of transmission.

M a n u s c r i p t 3 

Many hospitals now test all admitted patients for SARS-CoV-2 using polymerase chain reaction (PCR) assays. Patients with positive tests are placed in private rooms, cared for using specialized personal protective equipment, may have nonurgent procedures and treatments delayed, and are often unable to receive visitors. PCRpositivity, however, does not necessarily indicate infectiousness. SARS-CoV-2 RNA may be detected at low levels for weeks to months following an index illness but several studies have demonstrated that most immunocompetent patients are no longer contagious after 5-10 days and unlikely to be reinfected within the next 6 months. [1] [2] [3] [4] [5] Little is known, however, about the optimal approach to clinically assessing infectiousness in hospitalized patients who test positive by PCR, or the proportion of these patients who can be safely cared for using standard precautions. We therefore prospectively assessed all hospitalized patients with positive SARS-CoV-2 tests in a large academic hospital in Massachusetts during the 2020 winter COVID-19 surge for the necessity of isolation using an algorithm that incorporated SARS-CoV-2 history, symptoms, PCR cycle thresholds, and for some patients, repeat testing and serologies.

Brigham and Women's Hospital is an 803-bed academic hospital in Boston. We prospectively identified all adult hospitalized patients who tested positive for SARS-CoV-2 by PCR (primarily on the Hologic Panther Fusion or Cepheid Xpert platforms) between December 24, 2020-March 31, 2021 using a daily electronic report. During the study period, all patients were tested on admission via nasopharyngeal swabs A c c e p t e d M a n u s c r i p t 4 regardless of symptoms; patients with respiratory symptoms and an initial negative test were tested again after 12 hours to minimize the chance of a false negative given the relatively higher pre-test probability in this population. 6 Patients who were PCRnegative on admission were also tested 72 hours later to identify virus potentially incubating on arrival; testing was continued every 3 days through the first 14 days of hospitalization for patients undergoing aerosol-generating procedures. Testing was also encouraged for hospitalized patients with any new symptoms potentially consistent with COVID-19.

Patients with a known prior SARS-CoV-2 infection within 90 days were flagged as "COVID-Recovered" in our electronic health record system. As per CDC guidance, asymptomatic testing during this 90-day period (including admission testing) was discouraged via electronic best practice alerts and patients were managed on standard precautions. Testing was encouraged, however, if patients had new symptoms potentially consistent with COVID-19.

All PCR-positive patients were assessed by Infection Control for likely infectiousness and need for isolation. Patients with documentation of prior infection or cycle threshold (Ct) values ≥35 (on either platform) were assessed for the feasibility of early discontinuation of isolation using an algorithm that incorporated the presence or absence of symptoms potentially consistent with COVID-19, repeat PCR testing ≥24 hours later (to assess viral load kinetics and to ensure that high Ct values did not represent early acute infection 7 ), and if there was no known history of prior infection, SARS-CoV-2 serologies (Figure) . We used Ct values of ≥35 as a conservative threshold A c c e p t e d M a n u s c r i p t 5 based on studies that have been unable to recover viable virus when Ct values are >24 to 33. [1] [2] [3] [4] Serologies were performed using the Roche Elecsys Anti-SARS-CoV-2 antinucleocapsid total antibody assay, which has a sensitivity of 99.5% at ≥14 days following a PCR diagnosis and a specificity of 99.8%. 8 Non-infectious cases were classified as follows. Patients with serially high Ct values (or a repeat negative PCR test) were classified as having residual RNA from prior diagnosed (if known history of COVID-19) or undiagnosed (if no known history but reactive serologies) infection. Symptomatic patients were required to have alternate explanations for their symptoms (on case review, and on discussion with clinical teams) in addition to high and stable Ct values (or negative repeat tests) in order to have isolation discontinued. Patients with no known COVID-19 history with a repeat negative PCR test and non-reactive serologies were classified as likely false positives.

All cases were reviewed by one or more physician hospital epidemiologists (C.R., M.B., and M.K.) and discussed with patients' clinical teams prior to discontinuing isolation.

Cases deemed non-infectious were managed on standard precautions, which included face-masks and eye protection for providers and encouraging patients to wear face-masks during provider encounters. PCR-positive patients deemed potentially infectious continued to be managed with N95 respirators (or powered air purifying respirators) and gowns and gloves in addition to eye protection and patient masking. 

Written consent was not obtained from patients as the analysis was performed as part of routine hospital Infection Control operations. The study design was approved by the Mass General Brigham Institutional Review Board.

There were 11,583 patients admitted during the study period, of whom 175 were not tested due to being asymptomatic and "COVID-Recovered" (i.e., known 

Of the 536 PCR-positive patients, 381 (71.1%) were deemed potentially infectious as they were new diagnoses with low Ct values and/or progressive symptoms. In 28 of these cases, isolation was continued despite Ct values ≥35 due to 

During the winter COVID-19 second surge in Massachusetts, nearly 1 in 3 hospitalized patients who tested positive for SARS-CoV-2 by PCR were quickly deemed non-infectious and subsequently managed on standard precautions on the basis of clinical history, symptoms, repeat testing, and serologies in select cases. Most noninfectious patients had evidence of remote known or unknown infections. We did not find any evidence of SARS-CoV-2 transmission using this approach.

There is increasing recognition that PCR tests may "over-diagnose" COVID-19 by identifying people with remote infections that are no longer contagious. 9 Kobayashi et al. reported that 10 of 19 patients who tested positive by PCR after admission (mostly as A c c e p t e d M a n u s c r i p t 9 a result of serial asymptomatic screening) at a large Midwest tertiary medical center from July-September 2020 likely had prior infections using an approach similar to ours that incorporated Ct values, repeat tests, and serologies. 10 Our results expand on that analysis by comprehensively assessing all hospitalized patients who tested positive, including patients tested on admission. We frequently identified patients who had a prior undiagnosed infection, a phenomenon likely to become more common over time Our approach enabled many patients to be quickly released from isolation. This has substantial benefits for patients as isolation can delay procedures and other medical care, limit visitation and social supports, cause anxiety, and complicate post-discharge planning and home living situations. Our prospective assessments were also able to free up scarce private and airborne infection isolation rooms and avoid unnecessary consumption of personal protective equipment.

Our study has several limitations. First, the proportion of PCR-positive patients who are non-infectious may vary by hospitals' testing strategies and across labs, assays, and local epidemiology. Second, we were not able to definitively prove lack of A c c e p t e d M a n u s c r i p t 10 infectiousness with viral cell cultures. However, we did not identify any secondary transmissions after early discontinuation of isolation. Third, our results likely underestimated the true number of non-infectious patients, as many had high Ct values in the late stages of COVID-19 yet were continued on isolation due to progressive symptoms that were more likely due to post-infectious inflammatory changes than active SARS-CoV-2 infection. We also used a conservative Ct value threshold of ≥35 for our assessments; other studies suggest that the transmission risk becomes negligible at even lower Ct thresholds. 1 Our strategy of requiring repeat tests after 24 hours for asymptomatic patients with high Ct values also had a relatively low yield, as we only identified two patients who were clearly in the early acute phase based on a substantial drop in Ct value; a 3rd patient had a more mild decrease in Ct value and remained asymptomatic. None of these patients had evidence of prior infection. Our findings suggest that it is likely safe in most cases to discontinue precautions in asymptomatic PCR-positive patients with a history of prior infection after a single high Ct value. Given the risks associated with prematurely releasing patients from isolation and the increasing number of reported reinfections 14 , however, we deliberately erred on the side of caution.

In conclusion, during the 2020 winter COVID-19 second surge in Massachusetts, nearly 1 in 3 hospitalized patients who tested positive for SARS-CoV-2 by PCR were deemed non-infectious and were safely managed on standard precautions; most cases were consistent with residual RNA from prior known or unknown infections. Active assessments of SARS-CoV-2 PCR tests using clinical data, Ct values, repeat tests, and serologies can safely release many patients from isolation and thereby conserve hospital resources and facilitate patient care. collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?

Predicting infectious SARS-CoV-2 from diagnostic samples

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

Incidence of Nosocomial COVID-19 in Patients Hospitalized at a Large US Academic Medical Center

Viral dynamics of SARS-CoV-2 infection and the predictive value of repeat testing

Elecsys Anti-SARS-CoV-2: Product Information

Rethinking Covid-19 Test Sensitivity -A Strategy for Containment

COVID-19 Serial Testing among Hospitalized Patients in a Midwest Tertiary Medical Center

Estimated incidence of COVID-19 illness and hospitalization -United States

Estimation of US SARS-CoV-2 Infections, Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys

False-positive COVID-19 results: hidden problems and costs

Reinfection with SARS-CoV-2: Implications for Vaccines

Conflicts of Interest: Dr. Rhee and Dr. Klompas report royalties from UpToDate. None of the authors have any conflicts of interest to declare.

A c c e p t e d M a n u s c r i p t 12 A c c e p t e d M a n u s c r i p t PCR-positive patients who did not meet criteria for discontinuation of isolation outlined in the algorithm were assumed to be infectious and isolated as per CDC time/symptom-based criteria.A c c e p t e d M a n u s c r i p t